Amneal Pharmaceuticals LLC (NASDAQ: IPXL), a privately-held generic pharmaceutical manufacturing company headquartered in New Jersey, has agreed to a definitive business combination with California-based speciality pharmaceutical company, Impax Laboratories Inc., in an all-stock transaction, it was reported on Tuesday.
According to the deal, Amneal Holdings members will own approximately 75% and Impax shareholders will own approximately 25% of the new company's pro forma shares on an as converted basis.
The combined company is to be named Amneal Pharmaceuticals Inc., and will have a generics business that will rank as the fifth largest in the United States by gross revenue and a growing, high-margin specialty franchise. The companies said that the transaction is expected to enhance the combined organisation's competitive position and allow for continued success in an evolving generics market.
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval